Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKinsey
Harvard Business School
Medtronic
Dow

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Papaverine

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Papaverine: Sponsors, patents, clinical trial progress

Papaverine is an investigational drug.

There have been 13 clinical trials for Papaverine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2019.

The most common disease conditions in clinical trials are Erectile Dysfunction, Enuresis, and Schizophrenia. The leading clinical trial sponsors are National Cancer Institute (NCI), Hadassah Medical Organization, and The University of Texas Health Science Center, Houston.

There are two US patents protecting this investigational drug and twenty-two international patents.

Recent Clinical Trials for Papaverine
TitleSponsorPhase
Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric PatientsThe University of Texas Health Science Center, HoustonPhase 4
Papaverine Hydrochloride and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 1
Papaverine Hydrochloride and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung CancerOhio State University Comprehensive Cancer CenterPhase 1

See all Papaverine clinical trials

Clinical Trial Summary for Papaverine

Top disease conditions for Papaverine
Top clinical trial sponsors for Papaverine

See all Papaverine clinical trials

US Patents for Papaverine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Papaverine   Start Trial Methods and compositions for treating infection UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS)   Start Trial
Papaverine   Start Trial Implantable human liver tissue constructs and uses thereof Massachusetts Institute of Technology (Cambridge, MA)   Start Trial
Papaverine   Start Trial Cytochrome P450 fusion protein The University of York (York, GB) Sun Pharmaceutical Industries (Australia) Pty Ltd (Notting Hill, Victoria, AU)   Start Trial
Papaverine   Start Trial Matrix and layer compositions for protection of bioactives Novus International, Inc. (St. Charles, MO)   Start Trial
Papaverine   Start Trial Methods of inducing anesthesia The Regents of the University of California (Oakland, CA)   Start Trial
Papaverine   Start Trial Drug device configured for wireless communication Pop Test Abuse Deterrent Technology, LLC (Cliffside Park, NJ)   Start Trial
Papaverine   Start Trial Ultra-pure agonists of guanylate cyclase C, method of making and using same SYNERGY PHARMACEUTICALS, INC. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Papaverine

Drugname Country Document Number Estimated Expiration Related US Patent
Papaverine World Intellectual Property Organization (WIPO) 2014052836 2032-09-27   Start Trial
Papaverine World Intellectual Property Organization (WIPO) 2012048170 2030-10-06   Start Trial
Papaverine Australia 2015261278 2034-05-16   Start Trial
Papaverine Canada 2946812 2034-05-16   Start Trial
Papaverine European Patent Office 3143125 2034-05-16   Start Trial
Papaverine United Kingdom 201408729 2034-05-16   Start Trial
Papaverine United Kingdom 201506805 2034-05-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Express Scripts
Medtronic
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.